Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

0.1776 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sangamo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 6 Takes On Sangamo Therapeutics ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Sangamo Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
4 Analysts Have This To Say About Sangamo Therapeutics ↗
 
Via Benzinga
News headline image
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today? ↗
Sangamo Therapeutics stock is heading higher on Tuesday as SGMO investors react to a new $50 million license agreement. 
Via InvestorPlace
News headline image
Peering Into Sangamo Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Zeta Global, Spirit Airlines And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results ↗
 
Via Benzinga
News headline image
What's Going On With Sangamo Therapeutics Shares Tuesday? ↗
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving higher Tuesday after the company announced the FDA approved an accelerated pathway for ST-920, a potential gene therapy for the treatment of... 
Via Benzinga
News headline image
Crude Oil Rises Sharply; 3M Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Falls Over 150 Points; General Motors Tops Q3 Views ↗
 
Via Benzinga
Topics Stocks
News headline image
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
FDA Approves Pfizer's Second Hemophilia Drug With Six Months ↗
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly treatment reduces bleeding rates and offers convenience via an... 
Via Benzinga
News headline image
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Why Sangamo Therapeutics Stock Is Soaring ↗
Sangamo Therapeutics shares are trading higher Tuesday after the company announced it has entered into a license agreement with Genentech to develop intravenously administered genomic medicines for... 
Via Benzinga
News headline image
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today? ↗
Little-known firm Sangamo Therapeutics is surging today, with SGMO stock up more than 40% on promising late-stage trial results. 
Via InvestorPlace
News headline image
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings ↗
 
Via Benzinga
News headline image
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.